TITLE

Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04

AUTHOR(S)
Rayson, Daniel; Saint-Jacques, Nathalie; Younis, Tallal; Meadows, Jason; Dewar, Ron
PUB. DATE
January 2007
SOURCE
CMAJ: Canadian Medical Association Journal;1/30/2007, Vol. 176 Issue 3, p327
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Waiting times for cancer care continue to be an important issue for Canadians. We evaluated 2 cohorts of breast cancer patients to compare changes in elapsed times to care, to determine the proportion of patients who received their postoperative oncology consultation within the recommended time and to examine elapsed times between date of surgery and start of first adjuvant therapy. Methods: We conducted a retrospective chart review of all women with surgically treated breast cancer who were referred to a provincial cancer centre for adjuvant therapy. The first cohort comprised women referred between Sept. 1, 1999, and Sept. 1, 2000 (n = 342), and the second cohort comprised women referred between Sept. 1, 2003, and Sept. 1, 2004 (n = 295). A general linear model with a stepwise selection was used to identify dominant factors that influenced elapsed times; covariates included cohort period, age at diagnosis, place of residence, disease stage, type of surgery, type of adjuvant therapy, distance to cancer centre, median household income and mean education level. Results: The overall median time from disease detection to the start of first adjuvant therapy for the combined cohorts was 96 days (quartiles 76, 122); this interval was longer for patients in the second cohort (90 v. 102 days, p < 0.001). For the combined cohorts, significantly more patients saw a radiation oncologist within the recommended time from date of surgery than did patients referred to a medical oncologist (82.7% v. 51.7%; p < 0.001). Patients who received adjuvant radiation therapy as their first adjuvant treatment waited longer from the date of definitive surgery to the start of treatment than did patients who received chemotherapy or hormonal treatment (77 v. 48 or 42 days; p < 0.001). Interpretation: The median elapsed time from the detection of breast cancer to the start of first adjuvant therapy was longer in the second cohort (referred in 2003/04) than in the first cohort (referred in 1999/2000). The proportion of patients whose first oncology consultation was within the recommended timeframe varied significantly according to type of oncology specialist, favouring radiation oncology. Despite this difference in access, patients whose first adjuvant therapy was systemic therapy experienced significantly shorter elapsed times from surgery to the start of adjuvant therapy than did patients whose first adjuvant therapy was radiation therapy.
ACCESSION #
23761376

 

Related Articles

  • Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of care. Epstein, Richard J. // BMC Cancer;2007, Vol. 7, p92 

    Background: Diagnosis of breast cancer during pregnancy was formerly considered an indication for abortion. The pendulum has since swung to the other extreme, with most reviews now rejecting termination while endorsing immediate anthracycline-based therapy for any pregnant patient beyond the...

  • Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol. Kreuter, Michael; Vansteenkiste, Johan; Griesinger, Frank; Hoffmann, Hans; Dienemann, Hendrik; De Leyn, Paul; Thomas, Michael // BMC Cancer;2007, Vol. 7, p77 

    Background: Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor,...

  • OP66 Tumor Profiling Tests In Early Breast Cancer: A Systematic Review. Harnan, Susan; Cooper, Katy; Stevens, John; Wong, Ruth; Tappenden, Paul; Bessey, Alice; Ward, Sue; Rafia, Rachid; Stein, Rob; Brown, Janet // International Journal of Technology Assessment in Health Care;2018 Supplement, Vol. 34, p24 

    Introduction: Tumor profiling tests can help to identify whether women with breast cancer need chemotherapy due to their risk of relapse, and some may be able to predict benefit from chemotherapy. We focused on four genetic tests: Oncotype DX (O-DX), MammaPrint (MMP), EndoPredict and Prosigna,...

  • The Neuropsychology of Cancer and Oncology. Armstrong, Carol L. // Archives of Clinical Neuropsychology;Aug2014, Vol. 29 Issue 5, p497 

    No abstract available.

  • Carcinome métaplasique sein: à propos de cinq cas. Chraibi, M.; Znati, K.; Fatemi, H.; Chbani, L.; Belghiti, H.; Harmouch, T.; Bennis, S.; Amarti, A.; Kamaoui, I.; Tizniti, S.; Bouchikhi, C.; Bannani, M. // Oncologie;Oct2010, Vol. 12, p48 

    Metaplastic carcinoma of the breast is a rare and heterogeneous group of malignancies that accounts for less than 1% of all breast cancers. The histogenesis remains unknown. Clinical and radiological appearances are not specific. The treatment is based on surgery associated to radiation therapy...

  • Health care principles in breast Carcinoma patients. Tomic, Sanja; Popovic-Petrovic, Svetlana; Petrovic, Vasa // HealthMed;2010 Supplement 2, Vol. 4, p1095 

    No abstract available.

  • SIGN breast cancer guideline.  // Practice Nurse;1/27/2006, Vol. 31 Issue 2, p10 

    This article reports on the new guidelines on breast cancer issued by SIGN, Scotland's national clinical guidelines body, on breast cancer treatment as of January 2006. The new guideline provides the British National Health Service with recommendations based on advances in radiotherapy, surgery...

  • Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Kyung-Hun Lee; Seock-Ah Im; Do-Youn Oh; Se-Hoon Lee; Eui Kyu Chie; Wonshik Han; Dong-Wan Kim; Tae-You Kim; In Ae Park; Dong-Young Noh; Dae Seog Heo; Sung Whan Ha; Yung-Jue Bang // BMC Cancer;2007, Vol. 7, p63 

    Background: Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received the...

  • External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. Booth, Christopher M.; Dranitsaris, George; Gainford, M. Corona; Berry, Scott; Fralick, Michael; Fralick, John; Sue, Joanna; Clemons, Mark // BMC Cancer;2007, Vol. 7, p110 

    Background: Setting priorities for the funding of new anti-cancer agents is becoming increasingly complex. The funding of adjuvant trastuzumab for breast cancer has brought this dilemma to the fore. In this paper we review external factors that may influence decision-making bodies and present a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics